For a broader overview, see our dementia symptoms and diagnosis guide.
Blood Test Predicts: this caregiver-focused guide explains what blood test predicts means in plain English, the day-to-day implications for families, and when to bring it up with a clinician. If you arrived here looking for a quick orientation on blood test predicts, the table of contents below points to the section you need; the full guide picks up after it.
Table of contents
- Table of Contents
- What Are Blood Biomarker Tests for Dementia and How Early Can They Detect It?
- What Is the Current Medicare Part B Coverage Status?
- Which Blood Tests for Dementia Are FDA-Approved and Available Now?
- What Will These Tests Cost When Medicare Covers Them?
- How Can You Access These Tests Today If Medicare Doesn't Cover Them Yet?
- What Dementia-Related Services ARE Currently Covered by Medicare Part B?
- The Path Forward: When Will Medicare Likely Cover Dementia Blood Tests?
Despite recent headlines, blood tests for dementia screening are not yet covered by Medicare Part B—but that’s about to change. As of March 2026, while the FDA has approved groundbreaking blood biomarker tests that can detect Alzheimer’s disease pathology decades before symptoms appear, Medicare does not currently reimburse these tests for routine screening. However, the proposed Medicare ASAP Act aims to create a pathway for coverage, with final reimbursement decisions expected within the next year.
This shift represents a fundamental change in how dementia may be detected and managed in older adults, potentially enabling earlier interventions before cognitive decline becomes irreversible. The blood tests in question measure phosphorylated tau and beta-amyloid proteins in the blood—markers of Alzheimer’s pathology that previously could only be detected through expensive PET imaging or invasive cerebrospinal fluid taps. Recent FDA approvals of tests like the Lumipulse® G pTau 217/β-Amyloid 1-42 test (approved May 2025) and the ARUP pTau 217 test (launched April 2025) have made detection faster, cheaper, and more accessible. This article explores what these tests can do, why Medicare coverage hasn’t happened yet, what it might cost when it does, and how you can navigate dementia screening today.
Table of Contents
- What Are Blood Biomarker Tests for Dementia and How Early Can They Detect It?
- What Is the Current Medicare Part B Coverage Status?
- Which Blood Tests for Dementia Are FDA-Approved and Available Now?
- What Will These Tests Cost When Medicare Covers Them?
- How Can You Access These Tests Today If Medicare Doesn’t Cover Them Yet?
- What Dementia-Related Services ARE Currently Covered by Medicare Part B?
- The Path Forward: When Will Medicare Likely Cover Dementia Blood Tests?
- Conclusion
What Are Blood Biomarker Tests for Dementia and How Early Can They Detect It?
Blood biomarker tests for Alzheimer’s disease detect phosphorylated tau and beta-amyloid proteins circulating in the bloodstream—the same pathological hallmarks that accumulate in the brains of people with Alzheimer’s disease. The significance is staggering: these proteins can appear in the blood decades before cognitive symptoms emerge, giving doctors an unprecedented window for early intervention. A person might have completely normal memory and thinking abilities while these biomarkers are already present, indicating that Alzheimer’s pathology has begun its silent progression in the brain. The Lumipulse® G test approved in May 2025 specifically measures phosphorylated tau-217, a particularly sensitive marker of Alzheimer’s pathology. Similarly, the ARUP pTau 217 test launched in April 2025 serves the same purpose through a different laboratory platform.
These tests can identify people at risk decades before the cognitive decline that typically prompts a dementia evaluation. For example, a 55-year-old with no memory complaints might get a blood test and learn that Alzheimer’s pathology is already present, creating an opportunity to start lifestyle interventions, participate in clinical trials, or begin monitoring before irreversible cognitive loss occurs. The contrast between traditional and blood-based screening is dramatic. Previously, detecting Alzheimer’s pathology required either a PET scan (expensive, not widely available, often not covered by insurance) or a lumbar puncture to extract cerebrospinal fluid (invasive, uncomfortable, and carries small risks). A simple blood draw that can be done in any doctor’s office or lab is transformative in accessibility alone.
What Is the Current Medicare Part B Coverage Status?
Medicare Part B does not currently cover blood-based biomarker tests for routine dementia screening. This is true for private insurance, Medicare, and Medicaid as well—none of these payers have approved these tests as a covered service. The decision to deny coverage reflects uncertainty about clinical utility, cost-effectiveness, and how results should influence treatment decisions, rather than uncertainty about the tests’ technical accuracy. However, legislative action is underway.
The Medicare ASAP Act (Advancing Senior Access to Precision medicine through Appropriate Medicare coverage) proposes creating a pathway for Medicare to cover FDA-approved blood-based dementia screening tests. The Centers for Medicare & Medicaid Services (CMS) has begun developing Medicare billing codes for these tests, with codes expected to be available by January 2026. Despite this timeline, the reimbursement rates proposed by CMS have sparked controversy. An advisory panel recommended $130 per test to account for the complexity of measuring multiple biomarkers, but CMS initially proposed a rate of only $17 per test—just over 10% of the advisory recommendation. This dramatic gap suggests ongoing negotiations and delays before final coverage and payment decisions are finalized.
Which Blood Tests for Dementia Are FDA-Approved and Available Now?
Two major blood-based biomarker tests have achieved FDA approval or clinical laboratory launch in 2025. The Lumipulse® G pTau 217/β-Amyloid 1-42 test received FDA approval in May 2025 and is manufactured by Fujirebio, a leading diagnostics company. This test measures phosphorylated tau-217 and beta-amyloid 1-42, providing a comprehensive view of the two main pathological hallmarks of Alzheimer’s disease. The test has been studied extensively in research settings and now offers clinical laboratories a validated method for routine testing. ARUP Laboratories, a major hospital-affiliated clinical laboratory, launched its own pTau 217 test in April 2025.
ARUP’s platform serves hospitals and independent laboratories across the United States, making the test available to patients who have physician orders through their local healthcare systems. The availability of multiple platforms is important because it creates competition, potentially driving down prices over time and reducing regional access barriers. If a patient’s doctor wants to order a pTau 217 test, they can likely find a lab offering it through either Fujirebio’s Lumipulse platform or ARUP’s laboratory. Both tests are distinct from cognitive screening tools like the Montreal Cognitive Assessment (MoCA) or Mini-Cog, which actually test memory and thinking ability. These blood biomarkers don’t assess whether someone has cognitive problems—they assess whether the pathology underlying Alzheimer’s disease is present in the brain, even if the person still thinks and remembers normally.
What Will These Tests Cost When Medicare Covers Them?
The reimbursement debate reveals the economic stakes of widespread dementia screening. The Reimbursement Standards Committee, convened to advise CMS, recommended Medicare reimburse $130 per test for blood-based biomarker testing. This figure reflects the complexity of measuring multiple proteins, the technology required, and the labor involved in specimen processing and result interpretation. At $130 per test, the cost becomes reasonable from a population health perspective—comparable to or cheaper than existing diagnostic procedures like cognitive assessments. However, CMS’s initial proposed reimbursement rate of $17 per test would represent a dramatic cut from the advisory recommendation. At this rate, many laboratories would likely not offer the test because the reimbursement wouldn’t cover their operational costs.
This creates a paradox: Medicare could theoretically cover the test, but at a rate that makes it economically unsustainable for labs to perform. The final reimbursement decision will determine whether widespread Medicare coverage becomes practical or remains a hollow promise. Some advocacy organizations and clinical laboratories have strongly objected to the $17 figure, arguing that it would effectively exclude these tests from routine use despite FDA approval. For patients without Medicare, private insurance coverage remains inconsistent. Some employers’ plans may cover these tests as part of preventive health services, but many do not. Out-of-pocket costs at uninsured rates can range from $150 to $500 per test, depending on the laboratory and whether multiple biomarkers are measured.
How Can You Access These Tests Today If Medicare Doesn’t Cover Them Yet?
If you’re interested in blood biomarker testing despite the lack of Medicare coverage, several pathways exist. First, speak with your primary care doctor about your interest in dementia risk assessment. A physician can order the Lumipulse® G test or ARUP pTau 217 test through any major laboratory network (LabCorp, Quest Diagnostics, hospital labs, or ARUP directly). The test will be conducted as an out-of-pocket service, and you’ll be responsible for the full cost—typically $300 to $500 depending on which biomarkers are included. Second, you may qualify to participate in clinical research studies investigating these tests.
The Alzheimer’s Association maintains a research studies database where you can search for clinical trials recruiting participants for dementia biomarker studies. Participants in research sometimes receive free or reduced-cost testing as part of the study. Third, some academic medical centers and specialty neurology practices have begun offering these tests as part of comprehensive cognitive health evaluations, particularly if you have a family history of dementia or other risk factors. A critical limitation: be cautious about direct-to-consumer biomarker testing companies that claim to assess dementia risk. Some companies market blood tests directly to consumers without the rigorous validation that FDA-approved tests like Lumipulse have undergone. The Lumipulse® G test and ARUP pTau 217 test are your best assurance of accuracy because they’ve passed FDA review or rigorous clinical laboratory standards.
What Dementia-Related Services ARE Currently Covered by Medicare Part B?
While blood biomarker tests aren’t covered, Medicare Part B does reimburse cognitive assessment services that are medically necessary. This includes cognitive testing performed by a healthcare provider, care planning services related to cognitive impairment, and follow-up evaluations to monitor cognitive status. After meeting the annual deductible (which is $283 in 2026), you pay 20% coinsurance for these cognitive services.
A practical example: if you visit your doctor complaining of memory problems, the doctor can conduct a cognitive assessment using validated instruments like the Montreal Cognitive Assessment, order imaging (MRI, CT scan) to rule out stroke or tumor, and create a care plan to address your concerns. These services are covered because they involve evaluating an existing symptom. The distinction matters: Medicare covers cognitive assessment when someone is symptomatic but not when it’s used for preclinical screening of someone with completely normal cognition who happens to have Alzheimer’s pathology in their brain.
The Path Forward: When Will Medicare Likely Cover Dementia Blood Tests?
Legislation and regulatory timelines suggest Medicare coverage for dementia blood biomarker tests is coming but will require resolution of outstanding reimbursement disputes. Medicare billing codes are expected to be available by January 2026, indicating that the infrastructure is being prepared even as payment rates remain negotiated. The controversy over the $17 versus $130 reimbursement rate will likely be settled through additional discussions between CMS, clinical laboratories, medical societies, and advocacy organizations.
The ultimate timeline depends on political and budgetary factors beyond the scope of clinical evidence. The FDA has already validated these tests as safe and accurate. The remaining question is purely economic: at what price will Medicare reimburse these tests, and will that price make them practically available? Once reimbursement rates are finalized—expected sometime in 2026—Medicare Part B coverage could expand rapidly, transforming dementia screening from a specialty service into a routine preventive health offering available to millions of Medicare beneficiaries.
Conclusion
Despite headlines suggesting that blood biomarker tests for dementia are now covered by Medicare Part B, the reality as of March 2026 is that these tests are not yet a covered service. However, FDA approvals of the Lumipulse® G pTau 217 test (May 2025) and ARUP pTau 217 test (April 2025) represent genuine breakthroughs in detecting Alzheimer’s pathology decades before symptoms appear. The path to Medicare coverage is accelerating, with billing codes in development and the Medicare ASAP Act creating legislative momentum—but final reimbursement decisions remain pending.
If you’re interested in dementia risk screening now, your best options are working with your primary care doctor to order an FDA-approved test as an out-of-pocket service or exploring participation in clinical research studies. For those with Medicare today, cognitive assessment services are covered if symptoms are present, and you should take advantage of these covered preventive evaluations with your healthcare provider. Stay engaged with your doctor and the Alzheimer’s Association for updates on Medicare coverage decisions—when they’re finalized, access to early detection may fundamentally change how dementia is diagnosed and managed in older adults.
You Might Also Like
- The Blood Test Your Doctor May Not Know About That Predicts Dementia 25 Years Early
- The Blood Biomarker That Predicts Dementia 25 Years Early Is Now Available in 12 States
- Why Neurologists Say the New Dementia Blood Test Changes Everything About Early Prevention
Sources used for this Blood Test Predicts guide
- Alzheimer’s Association — Legal and Financial Planning
- National Institute on Aging — Legal and Financial Planning
- Medicare.gov
This article is informational and not medical advice. See our Editorial Policy for how we research and review content. Last reviewed May 30, 2026.
For more, see Alzheimer’s Association — clinical trials.
